Diagnosis and management of pemphigus: Recommendations of an international panel of experts
この論文をさがす
説明
BACKGROUND Several European countries recently developed international diagnostic and management guidelines for pemphigus, which have been instrumental in the standardization of pemphigus management, OBJECTIVE: We now present results from a subsequent Delphi consensus to broaden the generalizability of recommendations. METHODS A preliminary survey, based on the European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology (EADV) guidelines, was sent to a panel of international experts to determine the level of consensus. The results were discussed at the International Bullous Diseases Consensus Group in March 2016 during the annual American Academy of Dermatology (AAD) conference. A second survey was sent following the meeting to more experts to achieve greater international consensus. RESULTS The 39 experts participated in the first round of the Delphi-survey while 54 from 21 countries completed the second round. The number of statements in the survey was reduced from 175 topics in Delphi I to 24 topics in Delphi II based on Delphi results and meeting discussion. LIMITATIONS Each recommendation represents the majority opinion and therefore may not reflect all possible treatment options available. CONCLUSIONS We present here the recommendations resulting from this Delphi process. This international consensus includes intravenous CD20 inhibitors as a first line therapy option for moderate to severe pemphigus.
収録刊行物
-
- Journal of the American Academy of Dermatology
-
Journal of the American Academy of Dermatology 82 (3), 575-585.e1, 2020-03
Elsevier BV
- Tweet
キーワード
- CD20 / immunology
- Delphi Technique
- Plasmapheresis*
- [SDV]Life Sciences [q-bio]
- GUIDELINES
- Immunologic Factors / administration & dosage*
- Severity of Illness Index
- CD20 inhibitor consensus guidelines pemphigus foliaceus pemphigus vulgaris treatment
- consensu
- CD20 inhibitor
- guidelines
- Pemphigus / diagnosis*
- Combined Modality Therapy / methods
- treatment
- Academies and Institutes
- Plasmapheresis
- Dermatology / methods
- Combined Modality Therapy
- pemphigus foliaceu
- CD20 inhibitor ; consensus ; guidelines ; pemphigus foliaceus ; pemphigus vulgaris ; treatment.
- Europe
- Administration
- Combination
- Practice Guidelines as Topic
- Pemphigus / immunology
- Combination / methods
- Intravenous
- Rituximab
- Combined Modality Therapy / standards
- guideline
- Consensus
- pemphigus vulgaris
- Clinical Sciences
- Practice Guidelines as Topic*
- 610 Medicine & health
- Dermatology
- Rituximab / administration & dosage
- Drug Therapy
- pemphigus vulgari
- Humans
- Immunologic Factors
- Dermatology / standards
- CD20
- pemphigus foliaceus
- Antigens
- Glucocorticoids
- Dermatology & Venereal Diseases
- 028
- Pemphigus / therapy*
- consensus
- Combination / standards
- Academies and Institutes / standards
- Glucocorticoids / administration & dosage
- Pemphigus
- [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
- [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
詳細情報 詳細情報について
-
- CRID
- 1363107371184313344
-
- ISSN
- 01909622
-
- データソース種別
-
- Crossref
- OpenAIRE